Movement Alert｜Insmed Pre-Market Rise 17.15%, Q2 Earnings Massively Beat Expectations with Near-Breakeven EPS

Market Focus19:14

On August 6, Insmed rose 17.15% in pre-market trading, trading at approximately $115.95/share, with turnover of $1.5751 million. The surge was driven by the company's Q2 earnings report, which delivered results far exceeding Wall Street expectations across all key metrics.

Specifically, Insmed posted a Q2 loss of just $0.06 per share, dramatically beating the consensus estimate of a $0.73 loss by 91.78%, and representing a 96.47% improvement from the year-ago loss of $1.70 per share. Revenue came in at $425.49 million, surpassing the $392.84 million estimate by approximately 8.3% and showing significant sequential growth from Q1 revenue of $306 million. The near-breakeven EPS signals a major inflection point in profitability trajectory.

The results reflect strong commercial momentum for Brinsupri, which received UK marketing authorization earlier this year and has seen rising physician adoption. Analysts had previously projected over $1 billion in full-year Brinsupri revenue, with RBC Capital and Morgan Stanley maintaining Outperform and Overweight ratings respectively with consensus price targets near $197.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119149178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119149178","market":"us","top_or_hot":-1,"title":"Movement Alert｜Insmed Pre-Market Rise 17.15%, Q2 Earnings Massively Beat Expectations with Near-Breakeven EPS","media":"Market Focus","content":"<p><p>On August 6, Insmed rose 17.15% in pre-market trading, trading at approximately $115.95/share, with turnover of $1.5751 million. The surge was driven by the company's Q2 earnings report, which delivered results far exceeding Wall Street expectations across all key metrics.</p><p>Specifically, Insmed posted a Q2 loss of just $0.06 per share, dramatically beating the consensus estimate of a $0.73 loss by 91.78%, and representing a 96.47% improvement from the year-ago loss of $1.70 per share. Revenue came in at $425.49 million, surpassing the $392.84 million estimate by approximately 8.3% and showing significant sequential growth from Q1 revenue of $306 million. The near-breakeven EPS signals a major inflection point in profitability trajectory.</p><p>The results reflect strong commercial momentum for Brinsupri, which received UK marketing authorization earlier this year and has seen rising physician adoption. Analysts had previously projected over $1 billion in full-year Brinsupri revenue, with RBC Capital and Morgan Stanley maintaining Outperform and Overweight ratings respectively with consensus price targets near $197.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insmed Pre-Market Rise 17.15%, Q2 Earnings Massively Beat Expectations with Near-Breakeven EPS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insmed Pre-Market Rise 17.15%, Q2 Earnings Massively Beat Expectations with Near-Breakeven EPS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, Insmed rose 17.15% in pre-market trading, trading at approximately $115.95/share, with turnover of $1.5751 million. The surge was driven by the company's Q2 earnings report, which delivered results far exceeding Wall Street expectations across all key metrics.</p><p>Specifically, Insmed posted a Q2 loss of just $0.06 per share, dramatically beating the consensus estimate of a $0.73 loss by 91.78%, and representing a 96.47% improvement from the year-ago loss of $1.70 per share. Revenue came in at $425.49 million, surpassing the $392.84 million estimate by approximately 8.3% and showing significant sequential growth from Q1 revenue of $306 million. The near-breakeven EPS signals a major inflection point in profitability trajectory.</p><p>The results reflect strong commercial momentum for Brinsupri, which received UK marketing authorization earlier this year and has seen rising physician adoption. Analysts had previously projected over $1 billion in full-year Brinsupri revenue, with RBC Capital and Morgan Stanley maintaining Outperform and Overweight ratings respectively with consensus price targets near $197.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1119149178","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119149178","pubTimestamp":1786014898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, Insmed rose 17.15% in pre-market trading, trading at approximately $115.95/share, with turnover of $1.5751 million. The surge was driven by the company's Q2 earnings report, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"走势警报|Insmed 盘前上涨 17.15%，第二季度盈利大幅超出预期，每股收益接近盈亏平衡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"On August 6, Insmed rose 17.15% in pre-market trading, trading at approximately $115.95/share, with turnover of $1.5751 million. The surge was driven by the company's Q2 earnings report, which delivered results far exceeding Wall Street expectations across all key metrics.Specifically, Insmed posted a Q2 loss of just $0.06 per share, dramatically beating the consensus estimate of a $0.73 loss by 91.78%, and representing a 96.47% improvement from the year-ago loss of $1.70 per share. Revenue came in at $425.49 million, surpassing the $392.84 million estimate by approximately 8.3% and showing significant sequential growth from Q1 revenue of $306 million. The near-breakeven EPS signals a major inflection point in profitability trajectory.The results reflect strong commercial momentum for Brinsupri, which received UK marketing authorization earlier this year and has seen rising physician adoption. Analysts had previously projected over $1 billion in full-year Brinsupri revenue, with RBC Capital and Morgan Stanley maintaining Outperform and Overweight ratings respectively with consensus price targets near $197.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119149178","isCrawlerRequest":true}